Abstract: Objective The aim of this study was to study the clinical efficacy and treatment-related adverse reactions of high-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy in patients with locally advanced pancreatic cancer. Methods A total of 72 locally advanced pancreatic cancer patients who were admitted to Hefei Cancer Hospital of Chinese Academy of Sciences from September 2018 to November 2020 were selected and divided them into the control group of 36 cases and experimental group of 36 cases.The patients in the control group were given chemotherapy with nab-paclitaxel and Sigiroid, and the patients in the experimental group were given high-dose and less-fractionated radiotherapy for pancreatic cancer on the basis of the control group. Finally, 34 cases in the control group and 33 cases in the experimental group were included. The overall survival(OS), progression-free survival(PFS), Objective response rate(ORR), disease control rate(DCR),  and incidence of treatment-related adverse reactions were observed. Results The median OS and median PFS of the experimental group were 12.4 months and 6.3 months,respectively, which were longer than 8.5 months and 4.2 months in the control group(P＜0.05); the ORR was 21.21%,although higher than that in the control group(5.88%), but the difference is not statistically significant(P＞0.05); DCR was 66.67%, which was higher than that in the control group(38.24%)(P＜0.05); the levels of serum CEA, CA19-9,CA724 and CTC were significantly lower than those of the control group(P＜0.05). There was no significant difference in the incidence of fatigue,liver function damage,bone marrow suppression, sensory neurotoxicity, and pain/myalgia adverse reactions between the two groups(P＞0.05); the incidence of gastrointestinal reactions in the experimental group was higher than that in the control group(P＜0.05); but they were controllable and tolerable. Conclusion High-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy have significant clinical effects on patients with locally advanced pancreatic cancer, effectively prolonging survival period, and controllable treatment-related adverse reactions, which is worthy of clinical promotion.

Key words: Conformity, Dose-fractionation, Albumin-bound paclitaxel, Tiggio, Pancreatic neoplasms, Therapeutic effect